Nano-targeting vascular remodeling in cancer: Recent developments and future directions

Giordo, Roberta; Wehbe, Zena; Paliogiannis, Panagiotis; Eid, Ali H.; Mangoni, Arduino A.; Pintus, Gianfranco

doi:10.1016/j.semcancer.2022.03.001

Cited by 28 publications

(10 citation statements)

References 245 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PARP1 undergoes poly (ADP) ribosylation because of its affinity to DNA strand breaks. The process initiates the recruitment of additional DNA repair pathways as well as poly (ADP) ribosylation [ 32 ]. When PARP1 is inhibited, single-strand breaks (SSB) lesion repair fails, while double-strand breaks (DSB) repair remains unaffected.…”

Section: Current Treatment Of Ovarian Cancermentioning

confidence: 99%

Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer

Abujamous,

Soltani,

Al-Thawadi

et al. 2024

Biomol Biomed

View full text Add to dashboard Cite

Advanced ovarian cancer is a malignancy that spreads beyond the ovaries to the pelvis, abdomen, lungs, or lymph nodes. Effective treatment options are available to improve survival rates in patients with advanced ovarian cancer. These include radiation, surgery, chemotherapy, immunotherapy, and targeted therapy. Drug resistance, however, remains a significant challenge in pharmacotherapeutic interventions, leading to reduced efficacy and unfavorable patient outcomes. Combination therapy, which involves using multiple drugs with different mechanisms of action at their optimal dose, is a promising approach to circumvent this challenge and it involves using multiple drugs with different mechanisms of action at their optimal dose. In recent years, nanotechnology has emerged as a valuable alternative for enhancing drug delivery precision and minimize toxicity. Nanoparticles can deliver drugs to specific cancer cells, resulting in higher drug concentrations at the tumor site, and reducing overall drug toxicity. Nanotechnology-based drug delivery systems have the potential to improve the therapeutic effects of anti-cancer drugs, reduce drug resistance, and improve outcomes for patients with advanced ovarian cancer. This literature review aims to examine the current understanding of combining Poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapy in treating advanced ovarian cancer and the potential impact of nanotechnology on drug delivery.

show abstract

Section: Current Treatment Of Ovarian Cancermentioning

confidence: 99%

Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer

Abujamous,

Soltani,

Al-Thawadi

et al. 2024

Biomol Biomed

View full text Add to dashboard Cite

show abstract

“…Another mechanism of vascular remodeling in tumor cell metastasis is tumor cell infiltration and extravasation. During a specific stage of capillary endothelial cell remodeling, cancer cells successfully exudate and form new capillary rings, which is characteristic of invasive malignant tumor metastasis ( Giordo et al, 2022 ; Karreman et al, 2023 ). Unfortunately, limited knowledge exists regarding this pathway in terms of OS metastasis.…”

Section: Hif-1α and The Mechanism Of Os Metastasismentioning

confidence: 99%

Hypoxia inducible factor-1ɑ as a potential therapeutic target for osteosarcoma metastasis

Zhou,

Lan,

Liu

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Osteosarcoma (OS) is a malignant tumor originating from mesenchymal tissue. Pulmonary metastasis is usually present upon initial diagnosis, and metastasis is the primary factor affecting the poor prognosis of patients with OS. Current research shows that the ability to regulate the cellular microenvironment is essential for preventing the distant metastasis of OS, and anoxic microenvironments are important features of solid tumors. During hypoxia, hypoxia-inducible factor-1α (HIF-1α) expression levels and stability increase. Increased HIF-1α promotes tumor vascular remodeling, epithelial-mesenchymal transformation (EMT), and OS cells invasiveness; this leads to distant metastasis of OS cells. HIF-1α plays an essential role in the mechanisms of OS metastasis. In order to develop precise prognostic indicators and potential therapeutic targets for OS treatment, this review examines the molecular mechanisms of HIF-1α in the distant metastasis of OS cells; the signal transduction pathways mediated by HIF-1α are also discussed.

show abstract

“…In the early stage of tumor formation, the cancer cells are not allowed to enter the blood vessels and therefore do not metastasize throughout the body for the lack of tumor blood vessels. Once tumor blood vessels form, the cancer cells enter the human blood vessels through tumor blood vessels and metastasize to the liver, lung, stomach, brain, bone, and other normal functional organs with rich blood vessels and capillaries [67]. Thus, how to prevent tumor metastasis is of great significance, and exploring early diagnosis measures and prevention methods of tumor metastasis are essential for systematically addressing the problems associated with cancer treatment.…”

Section: Organic Semiconducting Small Moleculesmentioning

confidence: 99%

Insights into the organic semiconducting photosensitizers for hypoxia-tolerant type I photodynamic therapy

Hu¹,

Zhu²,

Sun³

et al. 2022

Nano TransMed

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a promising approach to treat cancer and microbial infections due to its minimal invasiveness, high spatiotemporal selectivity, tissue specificity, and low toxicity. Depending on the reactive oxygen species generation mechanisms, PDT can be classified as type I and type II. To date, most reported photosensitizers are based on the type II PDT mechanism, which produces toxic singlet oxygen and requires an abundant and continuous supply of oxygen molecules. Unfortunately, in typical solid tumor microenvironments, vascular abnormalities and rapid metabolisms lead to oxygen deficiency, severely compromising type II PDT's effectiveness. To address this issue, type I PDT with less oxygen consumption has been developed as an effective way to overcome the limitations of traditional type II PDT. In this contribution, we focus on the recent advances in type I organic semiconducting photosensitizers (OSPs), including organic semiconducting small molecules, conjugated polymers, and covalent organic frameworks for advanced hypoxia-tolerant PDT. The conceptual framework and general properties of these OSPs are firstly introduced, followed by introducing OSPs with different chemical structures for type I PDT. Finally, the overall conclusion, insightful perspective, and future direction of the efforts of OSPs for advanced biological applications are outlined.

show abstract

Nano-targeting vascular remodeling in cancer: Recent developments and future directions

Cited by 28 publications

References 245 publications

Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer

Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer

Hypoxia inducible factor-1ɑ as a potential therapeutic target for osteosarcoma metastasis

Insights into the organic semiconducting photosensitizers for hypoxia-tolerant type I photodynamic therapy

Contact Info

Product

Resources

About